Open Access
RESIDENT’S CORNER
Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy
Rutveej Patel1, Izak Faiena1, Jules Geltzeiler2
1
Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
2
Division of Urology, Jersey Shore University Medical Center, Neptune, New Jersey, USA
Address correspondence to Dr. Rutveej Patel, 1 Robert Wood
Johnson Place, MEB 584A, New Brunswick, NJ 08901 USA
Canadian Journal of Urology 2015, 22(2), 7752-7754.
Abstract
We present a case of a 75-year-old male with a history
of high risk prostate cancer who underwent androgen
deprivation therapy and palliative radiation treatments
for his disease. Subsequently, he presented with gross
hematuria and severe lower urinary tract symptoms. A
palliative transurethral resection of the prostate (TURP)
at that time, demonstrated large cell differentiated
neuroendocrine carcinoma with metastasis to the lung.
We review the limited literature on this rare form of disease
and present current treatment strategies.
Keywords
large cell neuroendocrine tumor, prostate cancer, hormone refractory prostate cancer, neuroendocrine differentiation
Cite This Article
APA Style
Patel, R., Faiena, I., Geltzeiler, J. (2015). Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy. Canadian Journal of Urology, 22(2), 7752–7754.
Vancouver Style
Patel R, Faiena I, Geltzeiler J. Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy. Can J Urology. 2015;22(2):7752–7754.
IEEE Style
R. Patel, I. Faiena, and J. Geltzeiler, “Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy,” Can. J. Urology, vol. 22, no. 2, pp. 7752–7754, 2015.
Copyright © 2015 The Canadian Journal of Urology.